A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02956837

Enrollment

406

Registered

2016-11-07

Start date

2016-11-10

Completion date

2018-02-05

Last updated

2019-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus Infections

Keywords

Vaccines, Respiratory Syncytial Viruses, Safety, Reactogenicity, Ranking of Formulations, Immunogenicity

Brief summary

The purpose of this study is to rank different RSV vaccine dosages of antigen (or formulations) based on safety/reactogenicity and immune response data. The formulations eliciting strong immune responses while maintaining an acceptable safety profile will be considered for further evaluation, including in studies vaccinating pregnant women.

Detailed description

The purpose of the RSV F-021 study that will be conducted in an observer-blind manner during Epoch 1 and single blinded during Epoch 2, is to rank the 3 different doses of the non-adjuvanted investigational RSV PreF-vaccine (30, 60 and 120 μg) based on safety/reactogenicity and immunogenicity data up to 1 month post-vaccination (Day 30). Non-pregnant women aged 18-45 years will be randomized in a 1:1:1:1 ratio to receive one of three dose levels (30, 60, 120 μg) of the RSV PreF vaccine or placebo. The doses eliciting strong immune responses while maintaining an acceptable safety profile will be considered for further evaluation, including in studies vaccinating pregnant women. This will allow evaluation of a wider antigen dose range to determine if there is a dose response relationship in terms of antibody response at the higher dose range that was not present at the lower range. Since in RSV F-021 the 120ug dosage of the PreF-based investigational RSV vaccine will be tested for the first time in humans, appropriate safety monitoring is planned for this study, including pausing enrolment when the first 25% of subjects from each study group have been vaccinated until review of day 7 post-vaccination safety data by an unblinded GSK internal Safety Review Committee (iSRC) has been completed. The enrolment/vaccination of the remaining subjects can only start following the favourable outcome of this iSRC safety review. In addition to study visits at Day 0, Day 7 and Day 30 to evaluate primary objective of the study, additional study visits are planned at Day 60 and 90 for further investigation of the immunogenicity and safety/reactogenicity profile of the formulations. A follow-up period has been set up in which the subjects will be contacted at Day 180, 270 and 360. During these contacts, the investigator (or delegate) will ask the subject if she has experienced any serious adverse events and/or any AEs leading to study withdrawal since Day 90/last contact (as applicable), as well as if she has become pregnant during the post-vaccination period. The investigator (or delegate) will also ask the subject about concomitant vaccinations/products/medications that she has received since Day 90/last contact (as applicable) and whether the she had a respiratory tract infection that needed medical attention. Contact should be preferably performed via telephone, or alternatively, if phone contact is not possible, through email/other means where the information can be fully collected. Healthy, non-pregnant women aged 18 - 45 years will be enrolled in this study: Women aged 18 - 45 years are selected to match the vaccine's target population, i.e. pregnant women, as closely as possible (gender, age). Non-pregnant women are selected to avoid unnecessarily exposing a vulnerable population (pregnant women and the foetuses/children) to a higher dose of the vaccine that has not previously been studied in non-pregnant women.

Interventions

BIOLOGICALRSV Vaccine (GSK3003891A) formulation 1

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

BIOLOGICALRSV Vaccine (GSK3003891A) formulation 2

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

BIOLOGICALRSV Vaccine (GSK3003891A) formulation 3

Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

DRUGPlacebo (Formulation buffer S9b)

A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject prior to performance of any study specific procedure. * Non-pregnant female between, and including, 18 and 45 years of age at the time of study vaccination. * Healthy subjects as established by medical history and clinical examination before entering into the study. * Female subjects of non-childbearing potential may be enrolled in the study * Non-childbearing potential is defined as pre-menarche, hysterectomy, ovariectomy or post-menopause. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * Has practiced adequate contraception for 30 days prior to study vaccination, and * Has a negative pregnancy test on the day of study vaccination, and * Has agreed to continue adequate contraception up to 90 days after vaccination.

Exclusion criteria

* Use of any investigational or non-registered product other than the study vaccines within 30 days prior to study vaccination, or planned use during the study period. * Concurrently participating in the active phase of another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. * Chronic administration of immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs, within 6 months prior to study vaccination, or planned administration until 90 days post-vaccination. For corticosteroids, this will mean prednisone ≥ 10 mg/day, or equivalent. Inhaled and topical steroids are allowed. * Administration of immunoglobulins and/or any blood products during the period starting 3 months before the study vaccination, or planned administration until 90 days post-vaccination. * Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before or after study vaccination. * Previous experimental vaccination against RSV. * History of any neurological disorders or seizures. * Family history of congenital or hereditary immunodeficiency. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination * History of or current autoimmune disease * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality as determined by physical examination and/or Medical History. * Lymphoproliferative disorder or malignancy within previous 5 years. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine. * Hypersensitivity to latex. * Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe. * Current alcohol and/or drug abuse. * Acute disease and/or fever at the time of enrolment. * Fever is defined as temperature ≥37.5°C for oral, axillary or tympanic route, or ≥ 38.0°C for rectal route. * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator. * For subjects with acute disease and/or fever at the time of enrolment, Visit 1/Day 0 will be rescheduled within the allowed recruitment period. * Body mass index (BMI) \> 40 kg/m². * Pregnant or lactating female. * Planned move to a location that will prohibit participating in the trial until study conclusion. * Any other condition that the investigator judges may interfere with study procedures or findings.

Design outcomes

Primary

Measure	Time frame	Description
Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited	During the 7-day (Days 0-6) post-vaccination period	Assessed solicited general AEs were fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], fever and headache. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.Grade 2 symptoms = occurrence of symptoms discomforting enough to interfere with daily activities. Grade 3 symptoms = symptoms that prevented normal activities. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).
Number of Subjects With Grade 2 and Grade 3 Fever	During the 7-day (Days 0-6) post-vaccination period	Grade 2 Fever was defined as oral temperature above (\>) 38.5 degrees Celsius (°C) to less than or equal to (≤) 39.5°C. Grade 3 Fever was defined as oral temperature \> 39.5°C. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).
Number of Subjects With Related Serious Adverse Events (SAEs)	During the 7-day (Days 0-6) post-vaccination period	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs = SAEs assessed by the investigator as related to the vaccination. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).
Neutralizing Antibody Titers Against RSV-A Subtype	At Day 0	RSV-A is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value greater than or equal to (≥) 8 ED60 (Estimated Dilution 60). This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).
Palivizumab Competing Antibody (PCA) Concentrations	At Day 0	PCA concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL), for a seropositivity cut-off ≥ 9.6 µg/mL. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).
Pavilizumab Competing Antibody (PCA) Concentrations	At Day 30	PCA concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL), for a seropositivity cut-off ≥ 9.6 µg/mL. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Secondary

Measure	Time frame	Description
Neutralizing Antibody Titers Against RSV-A Subtype	At Day 60 and Day 90	RSV-A is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value ≥ 8 ED60.
Neutralizing Antibody Titers Against RSV-B Subtype	At Day 0, Day 30, Day 60 and Day 90	RSV-B is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value ≥ 6 ED60.
Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	During the 7-day (Days 0-6) post-vaccination period	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 2 pain = painful when limb was moved and that interfered with every day activities.Grade 3 pain = significant pain at rest, pain that prevented normal every day activity. Grade 2 redness/swelling = redness/swelling spreading beyond (\>) 50 millimeters (mm) and up to (and including) 100 mm of injection site.Grade 3 redness/swelling = redness/swelling \> 100 mm of injection site. Medically attended symptoms = occurrence of symptoms that required medical advice.
Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	At Day 0 and Day 30	Anti-neogenin (anti-NEO) antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in nanograms per milliliter (ng/mL), for a seropositivity cut-off value ≥ 55 ng/mL.
Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV	From Day 0 up to study end, at Day 360	MA-RSV-RTIs were defined as a visit to a health care provider for respiratory symptoms including but not limited to cough, sputum production, difficulty breathing.
Palivizumab Competing Antibody (PCA) Concentrations	At Day 60 and Day 90	PCA concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL), for a seropositivity cut-off value ≥ 9.6 µg/mL.
Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	During the 7-day (Days 0-6) post-vaccination period	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (which include nausea, vomiting, diarrhoea and/or abdominal pain), headache, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 2 symptoms = occurrence of symptoms discomforting enough to interfere with daily activities. Grade 3 symptoms = symptoms that prevented normal activities.Related = symptom assessed by the investigator as related to the vaccination. Medically attended symptom = occurrence of symptom that required medical advice.
Number of Subjects With Any Unsolicited AEs	During the 30-day (Days 0-29) post-vaccination period	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Number of Subjects With Any SAEs	From Day 0 up to study end, at Day 360	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	At Day 7	Biochemical parameters assessed included alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine. Hematological parameters assessed included eosinophils, hemoglobin level, lymphocytes, neutrophils, platelet count and White Blood Cells \[WBC\]. Abnormal laboratory values at Day 7 were Below, Within and Above normal ranges, as compared to the baseline status of the same parameter, at Day 0 (Unknown, Below, Within and Above normal ranges) \[e.g. ALT Below - Within = ALT with below normal value at baseline and within normal values at Day 7\].
Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	From Day 7 up to Day 90	The biochemical and hematological parameters analyzed were ALT, AST, creatinine, eosinophils increase, hemoglobin decrease, lymphocytes decrease, neutrophils decrease, platelet count decrease, WBC decrease and WBC increase, which were graded by FDA Toxicity Grading Scale. Assessed grades over the Day 7- Day 90 period were Unknown, Grade 0 (=no grade), Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening), as compared to the baseline status of the same parameters, at Day 0 (Unknown, Grade 1, Grade 2, Grade 3) \[e.g. ALT Grade 0 - Unknown = ALT Grade 0 at baseline versus Unknown grade from Day 7 up to Day 90\].

Countries

Belgium, Estonia, France, Germany

Participant flow

Pre-assignment details

Out of 406 subjects initially enrolled in the study, 6 subjects had numbers allocated but did not receive any study vaccine dose, hence only 400 subjects were included in the Total Vaccinated Cohort.

Participants by arm

Arm	Count
GSK3003891A Vaccine Formulation 1 Group Subjects in this group received a single 30µg dose injection of the investigational GSK3003891A vaccine at Day 0.	100
GSK3003891A Vaccine Formulation 2 Group Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.	99
GSK3003891A Vaccine Formulation 3 Group Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.	99
Control Group Subjects in this group received a single placebo injection at Day 0.	102
Total	400

Withdrawals & dropouts

Period	Reason	FG001	FG002	FG003
Overall Study	Lost to Follow-up	1	2	0
Overall Study	Serious Adverse Events	1	0	0
Overall Study	Withdrawal by Subject	1	0	3

Baseline characteristics

Characteristic	GSK3003891A Vaccine Formulation 1 Group	GSK3003891A Vaccine Formulation 2 Group	GSK3003891A Vaccine Formulation 3 Group	Control Group	Total
Age, Continuous	30.2 Years STANDARD_DEVIATION 6.7	29.1 Years STANDARD_DEVIATION 7.2	29.6 Years STANDARD_DEVIATION 7.1	29.9 Years STANDARD_DEVIATION 6.9	29.7 Years STANDARD_DEVIATION 7
Race/Ethnicity, Customized Geographic Ancestry African Heritage/African American	1 Participants	0 Participants	2 Participants	1 Participants	4 Participants
Race/Ethnicity, Customized Geographic Ancestry Asian - Central/South Asian Heritage	1 Participants	1 Participants	0 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Geographic Ancestry Asian - East Asian Heritage	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Geographic Ancestry Asian - South East Asian Heritage	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized Geographic Ancestry Unspecified	2 Participants	0 Participants	1 Participants	1 Participants	4 Participants
Race/Ethnicity, Customized Geographic Ancestry White - Arabic/North African Heritage	0 Participants	1 Participants	2 Participants	1 Participants	4 Participants
Race/Ethnicity, Customized Geographic Ancestry White - Caucasian/European Heritage	96 Participants	97 Participants	93 Participants	98 Participants	384 Participants
Sex: Female, Male Female	100 Participants	99 Participants	99 Participants	102 Participants	400 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 100	0 / 99	0 / 99	0 / 102
other Total, other adverse events	88 / 100	86 / 99	83 / 99	76 / 102
serious Total, serious adverse events	1 / 100	3 / 99	2 / 99	2 / 102

Outcome results

Primary

Neutralizing Antibody Titers Against RSV-A Subtype

RSV-A is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value greater than or equal to (≥) 8 ED60 (Estimated Dilution 60). This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: At Day 0

Population: The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity at Day 30, which included all evaluable subjects who complied with the post-vaccination blood sampling schedule and for whom post-vaccination immunogenicity results were available for this assay at Day 0.

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-A Subtype	228.8 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-A Subtype	249.5 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-A Subtype	285.7 Titers
Control Group	Neutralizing Antibody Titers Against RSV-A Subtype	247.1 Titers

Primary

Neutralizing Antibody Titers Against RSV-A Subtype

RSV-A is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value ≥ 8 ED60 (Estimated Dilution 60). This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: At Day 30

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-A Subtype	858.2 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-A Subtype	1114.8 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-A Subtype	1245.5 Titers
Control Group	Neutralizing Antibody Titers Against RSV-A Subtype	271.6 Titers

Primary

Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited

Assessed solicited general AEs were fatigue, gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], fever and headache. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.Grade 2 symptoms = occurrence of symptoms discomforting enough to interfere with daily activities. Grade 3 symptoms = symptoms that prevented normal activities. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited	32 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited	30 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited	24 Participants
Control Group	Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited	27 Participants

Primary

Number of Subjects With Grade 2 and Grade 3 Fever

Grade 2 Fever was defined as oral temperature above (\>) 38.5 degrees Celsius (°C) to less than or equal to (≤) 39.5°C. Grade 3 Fever was defined as oral temperature \> 39.5°C. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had their symptom sheets filled in.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 2 Fever	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 3 Fever	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 3 Fever	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 2 Fever	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 2 Fever	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 3 Fever	0 Participants
Control Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 2 Fever	0 Participants
Control Group	Number of Subjects With Grade 2 and Grade 3 Fever	Grade 3 Fever	0 Participants

Primary

Number of Subjects With Related Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs = SAEs assessed by the investigator as related to the vaccination. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Related Serious Adverse Events (SAEs)	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Related Serious Adverse Events (SAEs)	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Related Serious Adverse Events (SAEs)	0 Participants
Control Group	Number of Subjects With Related Serious Adverse Events (SAEs)	0 Participants

Primary

Palivizumab Competing Antibody (PCA) Concentrations

PCA concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL), for a seropositivity cut-off ≥ 9.6 µg/mL. This primary objective focused only on subjects from the investigational GSK3003891A vaccine groups (GSK3003891A vaccine formulation 1 Group, GSK3003891A vaccine formulation 2 Group and GSK3003891A vaccine formulation 3 Group).

Time frame: At Day 0

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Palivizumab Competing Antibody (PCA) Concentrations	5.7 µg/mL
GSK3003891A Vaccine Formulation 2 Group	Palivizumab Competing Antibody (PCA) Concentrations	5.6 µg/mL
GSK3003891A Vaccine Formulation 3 Group	Palivizumab Competing Antibody (PCA) Concentrations	5.8 µg/mL
Control Group	Palivizumab Competing Antibody (PCA) Concentrations	6.0 µg/mL

Primary

Pavilizumab Competing Antibody (PCA) Concentrations

Time frame: At Day 30

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Pavilizumab Competing Antibody (PCA) Concentrations	66.8 µg/mL
GSK3003891A Vaccine Formulation 2 Group	Pavilizumab Competing Antibody (PCA) Concentrations	81.2 µg/mL
GSK3003891A Vaccine Formulation 3 Group	Pavilizumab Competing Antibody (PCA) Concentrations	83.7 µg/mL
Control Group	Pavilizumab Competing Antibody (PCA) Concentrations	6.1 µg/mL

Secondary

Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein

Anti-neogenin (anti-NEO) antibody concentrations were determined by ELISA, presented as geometric mean concentrations (GMCs) and expressed in nanograms per milliliter (ng/mL), for a seropositivity cut-off value ≥ 55 ng/mL.

Time frame: At Day 0 and Day 30

Population: This immunogenicity analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom immunogenicity results were available for this assay up to Day 30.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 0	32.9 ng/mL
GSK3003891A Vaccine Formulation 1 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 30	32.9 ng/mL
GSK3003891A Vaccine Formulation 2 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 30	31.5 ng/mL
GSK3003891A Vaccine Formulation 2 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 0	32.0 ng/mL
GSK3003891A Vaccine Formulation 3 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 0	33.5 ng/mL
GSK3003891A Vaccine Formulation 3 Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 30	33.1 ng/mL
Control Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 0	34.5 ng/mL
Control Group	Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein	Anti-NEO, Day 30	34.7 ng/mL

Secondary

Neutralizing Antibody Titers Against RSV-A Subtype

Time frame: At Day 60 and Day 90

Population: The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity at Day 90, which included all evaluable subjects who complied with the post-vaccination blood sampling schedule and for whom post-vaccination immunogenicity results were available for this assay up to Day 90.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 60	715.4 Titers
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 90	566.5 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 90	732.1 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 60	831.9 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 60	965.1 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 90	902.8 Titers
Control Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 60	311.6 Titers
Control Group	Neutralizing Antibody Titers Against RSV-A Subtype	Anti-RSV.A, Day 90	319.6 Titers

Secondary

Neutralizing Antibody Titers Against RSV-B Subtype

RSV-B is one of the two antigenically distinct subgroups of the Respiratory Synctial Virus (RSV). Antibody titers were determined by neutralization assay and presented as geometric mean titers (GMTs), for a seropositivity cut-off value ≥ 6 ED60.

Time frame: At Day 0, Day 30, Day 60 and Day 90

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 30	909.1 Titers
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 90	667.8 Titers
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 0	385.6 Titers
GSK3003891A Vaccine Formulation 1 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 60	752.1 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 0	392.1 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 90	804.9 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 30	1004.1 Titers
GSK3003891A Vaccine Formulation 2 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 60	847.1 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 0	410.6 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 90	848.6 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 60	923.6 Titers
GSK3003891A Vaccine Formulation 3 Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 30	1131.7 Titers
Control Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 90	423.2 Titers
Control Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 30	357.7 Titers
Control Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 60	409.6 Titers
Control Group	Neutralizing Antibody Titers Against RSV-B Subtype	Anti-RSV.B, Day 0	340.2 Titers

Secondary

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Biochemical parameters assessed included alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine. Hematological parameters assessed included eosinophils, hemoglobin level, lymphocytes, neutrophils, platelet count and White Blood Cells \[WBC\]. Abnormal laboratory values at Day 60 were Below, Within and Above normal ranges, as compared to the baseline status of the same parameter, at Day 0 (Unknown, Below, Within and Above normal ranges) \[e.g. ALT Below - Within = ALT with below normal value at baseline and within normal values at Day 60\].

Time frame: At Day 60

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with available results for each parameter analyzed, at Day 60.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	98 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	74 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	77 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	13 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	98 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	96 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	87 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	82 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	78 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	94 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	86 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	88 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	77 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	5 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	98 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	100 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	81 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	81 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	8 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	96 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	101 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	91 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	6 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	89 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	87 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	6 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	98 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants

Secondary

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Biochemical parameters assessed included alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine. Hematological parameters assessed included eosinophils, hemoglobin level, lymphocytes, neutrophils, platelet count and White Blood Cells \[WBC\]. Abnormal laboratory values at Day 7 were Below, Within and Above normal ranges, as compared to the baseline status of the same parameter, at Day 0 (Unknown, Below, Within and Above normal ranges) \[e.g. ALT Below - Within = ALT with below normal value at baseline and within normal values at Day 7\].

Time frame: At Day 7

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with available results for each parameter analyzed, at Day 7.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	74 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	8 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	77 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	12 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	88 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	7 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	81 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	87 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	86 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	79 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	98 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	81 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	100 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	6 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	88 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	94 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	102 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	99 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	8 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	82 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	87 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	100 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	3 Participants

Secondary

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Biochemical parameters assessed included alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine. Hematological parameters assessed included eosinophils, hemoglobin level, lymphocytes, neutrophils, platelet count and White Blood Cells \[WBC\]. Abnormal laboratory values at Day 30 were Below, Within and Above normal ranges, as compared to the baseline values of the same parameter, at Day 0 (Unknown, Below, Within and Above normal ranges) \[e.g. ALT Below - Within = ALT with below normal value at baseline and within normal values at Day 30\].

Time frame: At Day 30

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with available results for each parameter analyzed, at Day 30.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	76 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	80 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	13 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	88 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	94 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	94 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	91 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	82 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	79 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	94 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	88 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	94 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	96 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	92 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	75 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	5 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	8 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	86 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	88 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	90 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	100 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	99 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	95 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	101 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	87 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	97 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	83 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants

Secondary

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Biochemical parameters assessed included alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and creatinine. Hematological parameters assessed included eosinophils, hemoglobin level, lymphocytes, neutrophils, platelet count and White Blood Cells \[WBC\]. Abnormal laboratory values at Day 90 were Below, Within and Above normal ranges, as compared to the baseline status of the same parameter, at Day 0 (Unknown, Below, Within and Above normal ranges) \[e.g. ALT Below - Within = ALT with below normal value at baseline and within normal values at Day 90\].

Time frame: At Day 90

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with available results for each parameter analyzed, at Day 90.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	75 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	91 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	9 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	76 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	11 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	91 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	98 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	99 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	88 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	81 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	81 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	93 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Within	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	83 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	4 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	91 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	95 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	86 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	70 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	89 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	8 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	84 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	91 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	90 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Within	80 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Below	7 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Below	9 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Within	98 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Below	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Within	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Below	Below	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Hemoglobin, Within	Within	82 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Within	95 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Lymphocytes, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Within	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Within	99 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Within	92 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Within	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Within	Below	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Below	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	ALT, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Within	91 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Within	Above	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Within	89 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Within	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Neutrophils, Above	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Creatinine, Below	Below	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Within	Above	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Unknown	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Within	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Above	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Platelet count, Within	Within	95 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	AST, Within	Above	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	WBC, Above	Below	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities	Eosinophils, Within	Above	0 Participants

Secondary

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading

The biochemical and hematological parameters analyzed were ALT, AST, creatinine, eosinophils increase, hemoglobin decrease, lymphocytes decrease, neutrophils decrease, platelet count decrease, WBC decrease and WBC increase, which were graded by FDA Toxicity Grading Scale. Assessed grades over the Day 7- Day 90 period were Unknown, Grade 0 (=no grade), Grade 1 (=mild), Grade 2 (=moderate), Grade 3 (=severe) and Grade 4 (=potentially life-threatening), as compared to the baseline status of the same parameters, at Day 0 (Unknown, Grade 1, Grade 2, Grade 3) \[e.g. ALT Grade 0 - Unknown = ALT Grade 0 at baseline versus Unknown grade from Day 7 up to Day 90\].

Time frame: From Day 7 up to Day 90

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with available results for each parameter analyzed, during the considered period.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 2	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 0	100 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Unknown	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 0	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 3	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 0	94 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 0	92 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 1	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 0	90 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 0	96 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 0	95 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 1	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 1	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 0	94 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 1	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 3	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 0	61 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 1	14 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 2	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 3	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 0	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 1	11 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 2	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 3	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 0	98 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 1	10 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 4	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 0	80 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 2	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 3	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 1	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 0	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 1	9 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 0	95 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 1	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 0	70 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 0	74 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 1	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 0	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 1	20 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 0	98 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 0	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 0	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 1	12 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 0	85 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 0	97 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 1	9 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 2	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 0	94 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 0	96 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 1	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 1	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 0	73 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 0	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 1	15 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 0	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 1	5 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 2	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 0	99 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 1	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 0	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 0	94 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Grade 1	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 1	4 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 0	82 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 0	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 2	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 0	93 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 1	11 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 0	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 0	97 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 2	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 1	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 0	91 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 1	5 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 2	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 0	96 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 2	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 4	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 3	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Unknown	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 0	95 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 1	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 2	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 1	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 0	101 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	ALT, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 0	101 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	AST, Grade 1	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 0	102 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Creatinine, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 0	99 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 0	99 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 1	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Eosinophils increase, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 0	74 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 1	13 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 2	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 0	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 1	10 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 2	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 1	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 0	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 2	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Hemoglobin decrease, Grade 2	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 0	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Lymphocytes decrease, Grade 2	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 0	82 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 1	8 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 2	5 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 0	2 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 2	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 1	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 0	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 2	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Neutrophils decrease, Grade 2	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 0	100 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 1	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	Platelet count decrease, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 0	94 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 1	4 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 0	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 0	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 1	3 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC decrease, Grade 1	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 0	1 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 1	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 3	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Unknown	Grade 4	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Unknown	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 0	88 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 1	11 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 2	0 Participants
Control Group	Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading	WBC increase, Grade 0	Grade 3	0 Participants

Secondary

Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 2 pain = painful when limb was moved and that interfered with every day activities.Grade 3 pain = significant pain at rest, pain that prevented normal every day activity. Grade 2 redness/swelling = redness/swelling spreading beyond (\>) 50 millimeters (mm) and up to (and including) 100 mm of injection site.Grade 3 redness/swelling = redness/swelling \> 100 mm of injection site. Medically attended symptoms = occurrence of symptoms that required medical advice.

Time frame: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had their symptom sheets filled in.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Swelling (mm)	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Redness (mm)	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Pain	52 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Swelling (mm)	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Pain	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Pain	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Pain	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Redness (mm)	6 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Redness (mm)	2 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Redness	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Pain	5 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Redness	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Pain	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Swelling (mm)	6 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Redness (mm)	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Pain	52 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Redness (mm)	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Redness (mm)	10 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Pain	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Swelling (mm)	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Redness (mm)	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Pain	51 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Pain	10 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Pain	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Pain	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Redness (mm)	8 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Redness (mm)	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Redness	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Swelling (mm)	7 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Swelling (mm)	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Swelling (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Redness (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Redness (mm)	1 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Pain	11 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Swelling (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Pain	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Pain	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Swelling (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Swelling (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Medically-attended Redness (mm)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 3 Redness	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Grade 2 Pain	1 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs	Any Swelling (mm)	0 Participants

Secondary

Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (which include nausea, vomiting, diarrhoea and/or abdominal pain), headache, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 2 symptoms = occurrence of symptoms discomforting enough to interfere with daily activities. Grade 3 symptoms = symptoms that prevented normal activities.Related = symptom assessed by the investigator as related to the vaccination. Medically attended symptom = occurrence of symptom that required medical advice.

Time frame: During the 7-day (Days 0-6) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects who had their symptom sheets filled in.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Gastrointestinal symptoms	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Gastrointestinal symptoms	13 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Gastrointestinal symptoms	20 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Temperature/(Oral) (°C)	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Gastrointestinal symptoms	1 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Gastrointestinal symptoms	4 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Temperature/(Oral) (°C)	8 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Headache	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Fatigue	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Fatigue	47 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Headache	30 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Headache	3 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Fatigue	37 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Temperature/(Oral) (°C)	5 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Headache	11 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Headache	47 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Fatigue	0 Participants
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Fatigue	9 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Fatigue	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Fatigue	43 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Fatigue	14 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Fatigue	29 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Fatigue	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Gastrointestinal symptoms	23 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Gastrointestinal symptoms	3 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Gastrointestinal symptoms	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Gastrointestinal symptoms	17 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Gastrointestinal symptoms	0 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Headache	42 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Headache	11 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Headache	2 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Headache	27 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Headache	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Temperature/(Oral) (°C)	8 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Temperature/(Oral) (°C)	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Temperature/(Oral) (°C)	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Fatigue	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Gastrointestinal symptoms	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Headache	41 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Fatigue	36 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Temperature/(Oral) (°C)	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Headache	12 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Temperature/(Oral) (°C)	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Headache	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Fatigue	2 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Headache	33 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Fatigue	45 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Headache	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Fatigue	8 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Gastrointestinal symptoms	1 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Gastrointestinal symptoms	14 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Gastrointestinal symptoms	0 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Temperature/(Oral) (°C)	6 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Gastrointestinal symptoms	10 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Gastrointestinal symptoms	1 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Temperature/(Oral) (°C)	4 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Headache	29 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Gastrointestinal symptoms	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Fatigue	33 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Fatigue	42 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Fatigue	12 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Headache	37 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Fatigue	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Temperature/(Oral) (°C)	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Medically-attended Headache	0 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 2 Headache	10 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Fatigue	1 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Any Gastrointestinal symptoms	11 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Gastrointestinal symptoms	7 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Headache	3 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Grade 3 Gastrointestinal symptoms	1 Participants
Control Group	Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs	Related Temperature/(Oral) (°C)	2 Participants

Secondary

Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV

MA-RSV-RTIs were defined as a visit to a health care provider for respiratory symptoms including but not limited to cough, sputum production, difficulty breathing.

Time frame: From Day 0 up to study end, at Day 360

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV	21 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV	11 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV	10 Participants
Control Group	Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV	9 Participants

Secondary

Number of Subjects With Any SAEs

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame: From Day 0 up to study end, at Day 360

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any SAEs	1 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any SAEs	3 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any SAEs	2 Participants
Control Group	Number of Subjects With Any SAEs	2 Participants

Secondary

Number of Subjects With Any Unsolicited AEs

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame: During the 30-day (Days 0-29) post-vaccination period

Population: The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK3003891A Vaccine Formulation 1 Group	Number of Subjects With Any Unsolicited AEs	55 Participants
GSK3003891A Vaccine Formulation 2 Group	Number of Subjects With Any Unsolicited AEs	52 Participants
GSK3003891A Vaccine Formulation 3 Group	Number of Subjects With Any Unsolicited AEs	46 Participants
Control Group	Number of Subjects With Any Unsolicited AEs	49 Participants

Secondary

Palivizumab Competing Antibody (PCA) Concentrations

Time frame: At Day 60 and Day 90

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK3003891A Vaccine Formulation 1 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 60	55.2 µg/mL
GSK3003891A Vaccine Formulation 1 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 90	47.6 µg/mL
GSK3003891A Vaccine Formulation 2 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 90	57.9 µg/mL
GSK3003891A Vaccine Formulation 2 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 60	69.0 µg/mL
GSK3003891A Vaccine Formulation 3 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 60	66.7 µg/mL
GSK3003891A Vaccine Formulation 3 Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 90	57.0 µg/mL
Control Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 60	6.4 µg/mL
Control Group	Palivizumab Competing Antibody (PCA) Concentrations	PCA, Day 90	7.4 µg/mL

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Neutralizing Antibody Titers Against RSV-A Subtype

Neutralizing Antibody Titers Against RSV-A Subtype

Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited

Number of Subjects With Grade 2 and Grade 3 Fever

Number of Subjects With Related Serious Adverse Events (SAEs)

Palivizumab Competing Antibody (PCA) Concentrations

Pavilizumab Competing Antibody (PCA) Concentrations

Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein

Neutralizing Antibody Titers Against RSV-A Subtype

Neutralizing Antibody Titers Against RSV-B Subtype

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities

Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading

Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs

Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs

Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV

Number of Subjects With Any SAEs

Number of Subjects With Any Unsolicited AEs

Palivizumab Competing Antibody (PCA) Concentrations